BioNTech (BNTX) vs Halozyme Therapeutics (HALO)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Halozyme Therapeutics (HALO) has outperformed BioNTech (BNTX) over the past year, gaining 68.5% versus a loss of 13.4%. Over five years, HALO leads with a +190.9% price change compared with -62.8% for BNTX. BioNTech is the larger company by market cap ($24.36 billion vs $12.53 billion), about 1.9 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | BNTX | HALO |
|---|---|---|
| Share price | $96.96 | $110.42 |
| Market cap | $24.36B | $12.53B |
| 1-day change | +5.32% | +0.53% |
| YTD return | -3.30% | +63.21% |
| 1-year return | -13.38% | +68.47% |
| 5-year return | -62.83% | +190.89% |
| P/E ratio (TTM) | — | 32.29 |
| Forward P/E | — | 10.39 |
| EPS (TTM) | $-7.83 | $3.42 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | — | $1.40B |
| Revenue growth (YoY) | — | +37.55% |
| Net income (latest FY) | — | $316.89M |
| Gross margin | — | 83.62% |
| Operating margin | — | 33.58% |
| Net margin | — | 22.69% |
| 52-week high | $124.00 | $116.85 |
| 52-week low | $79.52 | $61.23 |
| Distance from 52-week high | -21.81% | -5.50% |
| Analyst consensus | buy | buy |
| Avg. price target upside | +19.42% | -9.84% |
| Average volume | 1.16M | 2.18M |
| Shares outstanding | 251.20M | 113.50M |
| Employees | 7,807 | 423 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- HALO has outperformed BNTX by 81.8 percentage points over the past year.
About BioNTech
BNTX stock →BioNTech SE, together with its subsidiaries, engages in the development and commercialization of immunotherapies in Germany. The company offers BNT162, an mRNA vaccine for the treatment of SARS-CoV-2 virus.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 7,807 employees
About Halozyme Therapeutics
HALO stock →Halozyme Therapeutics, Inc., a biopharmaceutical company, researches, develops, and commercializes of proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 423 employees
BNTX vs HALO FAQ
Which is bigger, BioNTech or Halozyme Therapeutics?
BioNTech (BNTX) is larger, with a market capitalization of $24.36B compared with $12.53B for Halozyme Therapeutics (HALO).
Which stock has performed better over the past year, BNTX or HALO?
HALO returned +68.47% over the past 12 months, compared with -13.38% for BNTX (price return, excluding dividends). Past performance does not predict future results.
Are BioNTech and Halozyme Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.